David Tong, M.D. , Scientist; Director of the Center for Stroke Research at CMPC

California Pacific CURRENTS: The online journal of CPMC Research Institute

Pioneering new advances in early diagnosis and treatment of stroke
  • Outcome of SMART patients compared with randomized clinical trials or pooled analyses

    Outcome of SMART patients compared with randomized clinical trials or pooled analyses.  Good outcome defined as mRS 0-1.(9, 10, 28-31).

    *Good outcome = Ranking 0-1 for NINDS/ECASS3 trial/CPMC data. ** SITS-MOST/ECASS 3 excluded patients > 80 y, stroke > 1/3 MCA, or “severe”, NIHSS > 25, ECASS 3 also excluded DM + prior stroke.

    Source: Tong D, et al. Neurology 2010. (Figure 2)

+

Research Overview

  • Dr. Tong is a nationally recognized leader in all aspects of stroke evaluation, including diagnosis and acute management, prevention and recovery. He is board certified in Neurology, Vascular Neurology and Neurocritical Care.
  • A former member of the National Institutes of Health Neurological Disease and Stroke (NINDS) Clinical Trials Review Committee, Dr. Tong designs and leads clinical studies in stroke and other neurologic illnesses.
  • Dr. Tong created one of the largest stroke telemedicine networks in Northern California—spanning two dozen facilities in the region—to facilitate expert diagnosis of stroke and initiation of effective treatment.
  • His team pioneered the use of SMART (Simplified Management of Acute Stroke using Revised Treatment) criteria for IV rt-PA treatment.
  • Dr. Tong is the Stroke/Neurointensive Care Lead for the Sutter Neuroscience Research Consortium.

Training

Dr. Tong obtained his M.D. from Baylor College of Medicine in Houston, Texas. He completed residency training in neurology at Stanford Medical Center in Palo Alto, California, and a stroke fellowship at Stanford Medical Center.


 

Publication Search

Publications

Koh JQ, Tong DC, Sriamareswaran R, Yeap A, Yip B, Wu S, Perera P, Menon S, Noaman SA, Layland J, In-hospital 'CODE STEMI' improves door-to-balloon time in patients undergoing primary percutaneous coronary intervention. Emerg Med Australas

Lessel D, Wu D, Trujillo C, Ramezani T, Lessel I, Alwasiyah MK, Saha B, Hisama FM, Rading K, Goebel I, Schütz P, Speit G, Högel J, Thiele H, Nürnberg G, Nürnberg P, Hammerschmidt M, Zhu Y, Tong DR, Katz C, Martin GM, Oshima J, Prives C, Kubisch C, Dysfunction of the MDM2/p53 axis is linked to premature aging. J Clin Invest

Jackson D, Tong D, Layland J, A review of the coronary applications of the drug coated balloon. Int J Cardiol

VIEW ALL
David Tong, M.D. , Scientist; Director of the Center for Stroke Research at CMPC
Primary Research Interests
  • Diagnosis and treatment of stroke

Research News & Highlights

Nobl Barazangi, MD, PhD, and David Tong, MD, published the Multi-SMART study in a February 2016 issue of the Journal of Stroke & Cerebrovascular Diseases. The SMART (Simplified Management of Acute Stroke using Revised Treatment Criteria) approach is a new method enabling physicians to quickly and efficiently determine which AIS patients will benefit from thrombolytic treatment.

Stroke Clinical Trials

Newsletters

Sign up to receive our newsletters

Sutter Neuroscience Research Consortium Newsletter